Akebia Therapeutics vs Cytokinetics
AKBA and CYTK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and CYTK compare
Akebia Therapeutics is the larger company, worth 18 times as much as Cytokinetics ($131M against $7.3M).
Cytokinetics grew revenue faster over the last twelve months (29.9% versus −12.4% for Akebia Therapeutics).
Akebia Therapeutics keeps more of each dollar of sales as profit, with a net margin of −22.6% compared with −687% at Cytokinetics.
Cytokinetics scores higher on the StockData Score (5 against 4 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | CYTK |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $7.3M |
| Share price | $0.474 | $56.13 |
| Change, 1 year | −74.4% | −14.9% |
| Change, 5 years | −82.9% | 37.4% |
| Beta (5Y) | 1.10 | 0.85 |
| Employees | 194 | 673 |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× | 0.1× (better) |
| P/B | 6.5× | – |
| P/FCF | 9.5× | – |
| FCF yield | 10.5% (better) | −8115% |
| Growth | ||
| Revenue growth (TTM) | −12.4% | 29.9% (better) |
| Revenue growth, 5Y average | −4.3% | 9.5% (better) |
| Profitability | ||
| Gross margin | 78.9% | – |
| Operating margin | −15.7% (better) | −625% |
| Net margin | −22.6% (better) | −687% |
| FCF margin | 7.0% (better) | −520% |
| Return on equity | −144% | – |
| Financial health | ||
| Debt / equity | 2.47 | – |
| Current ratio | 1.36 | 3.36 (better) |
| Altman Z-score | −6.30 | −3.80 (better) |
| Piotroski F-score | 7 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.7% | 115% |
| Held by insiders | 2.9% | 0.68% |
| Insider net buying, 12 months | −$876K (better) | −$51.5M |
| Short interest, % of float | 10.1% | 13.0% |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- CYTK stock overview
- CYTK income statement
- CYTK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.